Russell Investments Group
ARTV

Russell Investments Group’s Artiva Biotherapeutics ARTV Stock Holding History

Russell Investments Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.4K Hold
5,491
– – ﹤0.01% 3440
2025
Q4 		$23.6K Hold
5,491
– – ﹤0.01% 3571
2025
Q3 		$15.8K Hold
5,491
– – ﹤0.01% 3663
2025
Q2 		$8.29K Buy
+5,491
New +$11.5K ﹤0.01% 3367

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Russell Investments Group's ARTV Position: Q1 2026 in Review

Russell Investments Group held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 5,491 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3440.

Russell Investments Group first reported a position in ARTV in Q2 2025 and has held it in 4 quarters since. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Russell Investments Group held 5,491 shares of Artiva Biotherapeutics worth $35.4K as of Q1 2026.
  • Russell Investments Group left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3440 holding.
  • Russell Investments Group first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.